Based upon the clinical presentation of chronic fatigue syndrome (CFS), we hypothesized that proinflammatory cytokines may play a role in the pathogenesis of the disease. We therefore undertook a retrospective cross-sectional study to examine the role of TNF-α in patients with CFS. Our results suggest a significant increase serum TNF-α in patients with CFS (P < 0.0001) compared to non-CFS controls. This study supports the further examination of the role of proinflammatory mediators in CFS. Furthermore, the clinical testing of TNF-α blockers and other antiinflammatory agents for the treatment of this disease is warranted.
Unable to display preview. Download preview PDF.
- 1.Visser J, Blauw B, Hinloopen B, Brommer E, de Kloet ER, Kluft C, Nagelkerken L: CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis 177(2):451–454, 1998Google Scholar
- 2.Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL: Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 17(3):253–261, 1997Google Scholar
- 3.Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, Peterson PK, Komaroff AL: Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 17(2):160–166, 1997Google Scholar
- 4.Buchwald D, Wener MH, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 24(2):372–376, 1997Google Scholar
- 5.Levy JA: Viral studies of chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S117-S120, 1994Google Scholar
- 6.Krakauer T, Vilcek J, Oppenheim JJ: Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-β, and others. In Fundamental Immunology, 4th ed, WE Paul (ed). New York, Lippincott-Raven, 1999, pp 775–811Google Scholar
- 7.Feldmann M, Brennan FM, Maini R: Cytokines in autoimmune disorders. Int Rev Immunol 17(1–4):217–228, 1998Google Scholar
- 8.Gupta S, Aggarwal S, See D, Starr A: Cytokine production by adherent and nonadherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 31(1):149–156, 1997Google Scholar
- 9.Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Muller WE, Schroder HC, Carter WA, et al.: Upregulation of the 2–5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S96-S104, 1994Google Scholar
- 10.Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al.: A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S88-S95, 1994Google Scholar
- 11.Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 28;304(4):253–259, 1999Google Scholar
- 12.Bauditz J, Lochs H, Schreiber S: Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 29;338(5):334, 1998Google Scholar